SnagRx vs LTTL: Compounded GLP-1 pricing, shipping, and oversight
SnagRx vs LTTL: SnagRx is the lower-cost compounded option on a 12-month plan with price locked at every dose and named US 503A partner pharmacies. LTTL advertises compounded GLP-1s with up to $140 off the first month and states medications are prepared in state licensed pharmacies and verified in FDA registered labs. Early verdict: For predictable long term pricing choose SnagRx; for an upfront first-month credit and lab verification claims consider LTTL.
See SnagRx pricing and plan options
Overview: SnagRx vs LTTL
The primary difference between SnagRx and LTTL is how each frames price certainty, pharmacy sourcing, and promotional terms. SnagRx lists compounded semaglutide from $69/month on a 12-month plan and says the rate is locked flat at every dose. LTTL highlights an auto-applied code for up to $140 off the first month and emphasizes state licensed pharmacies and independent lab verification. Both offer compounded GLP-1 medications; both note compounded medications are not FDA approved.
Side by side comparison
| Criteria | SnagRx | LTTL |
|---|---|---|
| Starting price | Semaglutide from $69/month on 12-month plan; month-to-month $99 | Up to $140 off first month; specific ongoing price not verified on capture |
| Price structure | Price locked flat at every dose and at renewal on annual plan | Promotes same price every dose; promotional credit applies to first month |
| Pharmacy sourcing and testing | Names four US 503A partner pharmacies and states LegitScript certification | Compounded by state licensed pharmacies; claims independent verification in FDA registered labs |
| Clinician review and coverage | OpenLoop Health clinician network; clinician review typically within 5 hours; covers 48 states | Treatment available only when a licensed clinician determines it is appropriate; state coverage not fully detailed |
| Shipping and timing | Next-day UPS/FedEx in temperature controlled packaging; free shipping claimed | Delivered to your door when needed; specific timing not captured |
| Guarantees and refunds | Full refund if prescription declined; mentions a 6-month weight-loss guarantee with terms | No expanded guarantee details captured; terms may change and were not verified |
Pricing and commitment: predictability versus promotional credit
SnagRx makes the price mechanics clear: the $69 semaglutide rate and $119 tirzepatide rate are 12-month plan prices and the company says the rate is locked through titration and renewal. Month-to-month equivalents are $99 and $149. LTTL highlights an auto-applied code for up to $140 off the first month but captured affiliate landing details did not publish ongoing rates or renewal terms. If you need a locked long term rate SnagRx documents that feature explicitly; if you prioritise a first-month credit LTTL advertises that promotion.
Compare SnagRx annual versus month-to-month pricing
Pharmacy sourcing and quality verification
Both providers supply compounded medications and both include the regulatory note that compounded medications are not FDA approved and are not reviewed by FDA for safety, effectiveness or quality. SnagRx names its four US 503A partner pharmacies and states LegitScript certification. LTTL states medications are compounded by state licensed pharmacies and independently verified in FDA registered labs with potency checks every 3 to 6 months. The evidence shows SnagRx emphasizes named partners and a clinician network while LTTL emphasizes lab verification claims on the captured landing page.
Clinician review, state coverage and shipping
SnagRx documents that OpenLoop Health clinicians typically review intake within five hours and that approved orders ship next-day in temperature-controlled packaging. SnagRx also notes clinician coverage across 48 states. LTTL states treatment is available only when a licensed clinician determines it is medically appropriate and that medications are delivered to your door, but the captured page did not publish specific clinician response times or full state coverage details. If fast clinician review and next-day shipping are priorities the captured SnagRx evidence lists those timelines explicitly.
Check LTTL eligibility and promotional credit details
Guarantees, terms and marketing
SnagRx advertises a full refund if a prescription is declined and mentions a 6-month weight-loss guarantee with terms. The captured LTTL evidence did not include expanded guarantee or refund details and cautions that pricing, eligibility, pharmacy, state coverage and renewal terms may change. Both use promotional language; SnagRx includes urgency elements on its pricing page.
Regulatory note and safety language
Both providers state compounded medications are not FDA approved and are not reviewed by the FDA for safety, effectiveness or quality. SnagRx additionally encourages prospective users to speak with their provider about specific risks and explains that OpenLoop clinicians will determine prescription eligibility after intake. LTTL notes treatment is available only when a licensed clinician determines it is medically appropriate.
Review SnagRx clinician and pharmacy disclosures
Conclusion: SnagRx vs LTTL
SnagRx and LTTL both offer compounded GLP-1 options but differ on the priorities they present. SnagRx documents bottom-of-market annual pricing with a flat price lock, named US 503A pharmacies, a documented clinician network and faster review and shipping claims. LTTL highlights an up-to-$140 first-month credit and states its medications are compounded by state licensed pharmacies and verified in FDA registered labs. Both note compounded medications are not FDA approved.
Visit LTTL to confirm current pricing and state availability
Choose SnagRx if you want predictable, locked-in annual pricing, named 503A pharmacies, and documented clinician review and next-day shipping in the captured evidence. Choose LTTL if you prioritise an auto-applied first-month credit and the provider statements about state licensed pharmacies and independent lab verification, remembering that captured renewal and state coverage details were not fully published.